The regulation on European Health Technology Assessment (EU HTA) entered into force on 11
January 2022 and will apply from 12 January 2025. It introduces joint clinical assessments and
joint scientific consultations at the European level for new health technologies including
pharmaceuticals and medical devices. While market access pricing and reimbursement will
continue to be the responsibility of EU member states EU HTA will nevertheless have an immense
impact on these national market access activities. This book serves as a practical guide
designed to help developers of pharmaceuticals prepare for the upcoming EU HTA process.
